A thin endometrium can feel like an invisible wall between you and your dream of becoming a mother. For many women, it is the hidden reason behind failed implantation, recurrent miscarriages, and repeated disappointment during IVF cycles. While traditional treatments often provide only partial solutions, science is opening a new chapter in reproductive health. Today, regenerative medicine offers real hope for women diagnosed with thin endometrium or Asherman syndrome, helping them move from frustration to possibility.
What Is thin endometrium and why does it matter?
The endometrium is the uterine lining where an embryo implants and grows. A healthy lining measures between 8–12 mm during the implantation window. When it does not exceed 7 mm, doctors refer to it as thin endometrium. Why thickness matters:
- Lower implantation rates during IVF
- Higher risk of early pregnancy loss
- Increased cycle cancellations
- Emotional and financial strain for couples
Causes of thin endometrium
Several factors may lead to a persistently thin uterine lining:
- Hormonal imbalances – low estrogen levels reduce tissue growth.
- Uterine infections and chronic inflammation – conditions such as chronic endometritis can impair uterine receptivity.
- Asherman syndrome – scar tissue inside the uterus disrupts normal regeneration.
- Aging and reduced responsiveness – the endometrial stem cell niche loses function over time.
How thin endometrium affects fertility
A thin lining compromises the chances of carrying a pregnancy, even when high-quality embryos are transferred. Many women experience:
- Repeated failed implantation in IVF cycles
- Recurrent miscarriages
- Infertility with no clear cause
For women in their 30s and 40s, this reality can be emotionally devastating, fueling frustration and loss of confidence in traditional fertility treatments. Conventional treatments: helpful but limited Historically, doctors have recommended:
- Estrogen therapy – to stimulate the lining, with variable results.
- Surgical adhesiolysis – removal of adhesions in women with Asherman syndrome.
- PRP (platelet-rich plasma) – a supportive but experimental option.
While these methods may help some women, many continue to face the same barrier: a lining that does not respond as expected.
Regenerative medicine: a breakthrough in reproductive health
Here is where science offers renewed hope. Stem cell–based therapies are designed to regenerate damaged endometrial tissue instead of temporarily stimulating it. How it works Autologous CD133+ stem cells (taken from your own bone marrow) are mobilized, collected, and reintroduced into the uterine arteries. Once there, they:
- Promote blood vessel growth (angiogenesis)
- Stimulate regeneration of the basal layer
- Reduce scarring and fibrosis
- Improve receptivity for embryo implantation
PAULA Cell Therapy: restoring fertility with your own cells
Developed by Endorenew, PAULA Cell Therapy is the first regenerative treatment scientifically validated for thin endometrium and Asherman syndrome. Clinical evidence shows:
- Significant improvement in endometrial thickness and volume
- Reduction of intrauterine adhesions after treatment
- Higher implantation and live birth rates compared with conventional therapies (up to 30% live births in women previously considered untreatable)
- Safety and compatibility thanks to the use of each woman’s own cells
Why it matters Unlike hormones or repeated surgeries, PAULA addresses the root cause of a thin endometrium: impaired regeneration. It offers a scientifically backed path to restore uterine function and increase the chances of a healthy pregnancy. Who can benefit? You may be a candidate for regenerative therapy if you:
- Have a history of thin endometrium (<7 mm) despite hormone therapy
- Experienced failed implantation after multiple IVF cycles
- Have been diagnosed with Asherman syndrome or uterine scarring
- Are between 30–45 years old and wish to conceive
A message of hope A thin endometrium is not a sentence—it is a signal. Thanks to advances in reproductive medicine, women who were once told they had no chance of conceiving now have options grounded in science and compassion. If you are struggling with fertility due to thin endometrium or Asherman syndrome, know that there are evidence-based solutions ready to help you move from frustration to hope. We are currently identifying potential patients for our Phase III clinical trial with PAULA Cell Therapy that is currently in the design and regulatory review phase. If you want more information, just write us at inquires.